Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2000-07-21
2008-09-02
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S050000
Reexamination Certificate
active
07419968
ABSTRACT:
This invention provides methods for using novel substituted pyrimidine compounds, derivatives and analogs thereof to treat diseases such as cancer. Examples of compounds and derivatives for use in the methods are (E)-5-(2-bromovinyl)-2′-deoxy-5′-uridyl phenyl L-alaninylphosphoramidate and (E)-5-(2-bromovinyl)-2′-deoxy-5′-uridyl phenyl L-alaninyl monophosphate.
REFERENCES:
patent: 3852266 (1974-12-01), Kiyanagi et al.
patent: 4247544 (1981-01-01), Bergstrom et al.
patent: 4267171 (1981-05-01), Bergstrom et al.
patent: 4542210 (1985-09-01), Sakata et al.
patent: 4668777 (1987-05-01), Caruthers et al.
patent: 4816570 (1989-03-01), Farquhar
patent: 4948882 (1990-08-01), Ruth
patent: 4963263 (1990-10-01), Kauvar
patent: 4963533 (1990-10-01), de Clercq et al.
patent: 4975278 (1990-12-01), Senter et al.
patent: 5070082 (1991-12-01), Murdock et al.
patent: 5077282 (1991-12-01), Murdock et al.
patent: 5077283 (1991-12-01), Murdock et al.
patent: 5085983 (1992-02-01), Scanlon
patent: 5116822 (1992-05-01), De Clercq et al.
patent: 5116827 (1992-05-01), Murdock et al.
patent: 5133866 (1992-07-01), Kauvar
patent: 5137724 (1992-08-01), Balzarini et al.
patent: 5212161 (1993-05-01), Moriniere et al.
patent: 5212291 (1993-05-01), Murdock et al.
patent: 5217869 (1993-06-01), Kauvar
patent: 5233031 (1993-08-01), Borch et al.
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5274162 (1993-12-01), Glazier
patent: 5300425 (1994-04-01), Kauvar
patent: 5338659 (1994-08-01), Kauvar et al.
patent: 5430148 (1995-07-01), Webber et al.
patent: 5433955 (1995-07-01), Bredehorst et al.
patent: 5457187 (1995-10-01), Gmeiner et al.
patent: 5459127 (1995-10-01), Felgner et al.
patent: 5502037 (1996-03-01), Kondratyev
patent: 5516631 (1996-05-01), Frisch
patent: 5521161 (1996-05-01), Malley et al.
patent: 5527900 (1996-06-01), Balzarini et al.
patent: 5556942 (1996-09-01), Kauvar et al.
patent: 5596018 (1997-01-01), Baba et al.
patent: 5616564 (1997-04-01), Rapaport et al.
patent: 5627165 (1997-05-01), Glazier
patent: 5643893 (1997-07-01), Benson et al.
patent: 5645988 (1997-07-01), Vande Woude et al.
patent: 5663321 (1997-09-01), Gmeiner et al.
patent: 5733896 (1998-03-01), Holy et al.
patent: 5798340 (1998-08-01), Bischofberger et al.
patent: 5968910 (1999-10-01), Balzarini
patent: 5981507 (1999-11-01), Josephson et al.
patent: 6057305 (2000-05-01), Holy et al.
patent: 6245750 (2001-06-01), Shepard
patent: 6339151 (2002-01-01), Shepard et al.
patent: 6495553 (2002-12-01), Shepard
patent: 6589941 (2003-07-01), Fahrig et al.
patent: 6599499 (2003-07-01), Rosen et al.
patent: 6677314 (2004-01-01), Klecker et al.
patent: 6677315 (2004-01-01), Klecker et al.
patent: 6682715 (2004-01-01), Klecker et al.
patent: 6683045 (2004-01-01), Klecker et al.
patent: 6683061 (2004-01-01), Shepard et al.
patent: 6703374 (2004-03-01), Klecker et al.
patent: 6753309 (2004-06-01), Klecker et al.
patent: 2001/0034440 (2001-10-01), Shepard et al.
patent: 2002/0022001 (2002-02-01), Klecker et al.
patent: 2002/0034473 (2002-03-01), Klecker et al.
patent: 2002/0119094 (2002-08-01), Klecker et al.
patent: 2002/0147175 (2002-10-01), Shepard et al.
patent: 2002/0151519 (2002-10-01), Shepard
patent: 2002/0165199 (2002-11-01), Klecker et al.
patent: 2003/0049201 (2003-03-01), Klecker et al.
patent: 2003/0095921 (2003-05-01), Klecker et al.
patent: 32 29 169 (1984-02-01), None
patent: 0095294 (1983-11-01), None
patent: 0283065 (1988-09-01), None
patent: 0 311 107 (1989-04-01), None
patent: 0 311 108 (1989-04-01), None
patent: 0 316 592 (1989-05-01), None
patent: 982776 (1965-02-01), None
patent: 88451 (1986-01-01), None
patent: WO 89/05817 (1989-06-01), None
patent: WO 90/03978 (1990-04-01), None
patent: WO 91/17424 (1991-11-01), None
patent: WO 92/19767 (1992-11-01), None
patent: WO 92/20344 (1992-11-01), None
patent: WO 93/06120 (1993-04-01), None
patent: WO 94/03467 (1994-02-01), None
patent: WO94/22483 (1994-10-01), None
patent: WO 94/22483 (1994-10-01), None
patent: WO 95/01806 (1995-01-01), None
patent: WO95/08556 (1995-03-01), None
patent: WO 95/08556 (1995-03-01), None
patent: WO 95/09865 (1995-04-01), None
patent: WO 95/12678 (1995-05-01), None
patent: WO 96/03151 (1996-02-01), None
patent: WO96/03151 (1996-02-01), None
patent: WO 96/07431 (1996-03-01), None
patent: WO96/07431 (1996-03-01), None
patent: WO 96/10300 (1996-04-01), None
patent: WO96/10300 (1996-04-01), None
patent: WO 96/23506 (1996-08-01), None
patent: WO 96/29336 (1996-09-01), None
patent: WO 96/33168 (1996-10-01), None
patent: WO 96/40088 (1996-12-01), None
patent: WO96/40708 (1996-12-01), None
patent: WO 96/40708 (1996-12-01), None
patent: WO 96/40739 (1996-12-01), None
patent: WO 97/25342 (1997-07-01), None
patent: WO97/28179 (1997-08-01), None
patent: WO 97/28179 (1997-08-01), None
patent: WO 97/49717 (1997-12-01), None
patent: WO 98/49177 (1998-11-01), None
patent: WO 99/06072 (1999-02-01), None
patent: WO 99/08110 (1999-02-01), None
patent: WO 99/20741 (1999-04-01), None
patent: WO99/20741 (1999-04-01), None
patent: WO 99/23104 (1999-05-01), None
patent: WO 99/37753 (1999-07-01), None
patent: WO 00/18775 (2000-04-01), None
patent: WO 00/33888 (2000-06-01), None
patent: WO 01/07088 (2001-02-01), None
patent: WO 01/07454 (2001-02-01), None
patent: WO01/07454 (2001-02-01), None
patent: WO 01/83501 (2001-11-01), None
patent: WO 01/85749 (2001-11-01), None
Firestone et al., “A Comparison of the Effects of Antitumor Agents Upon Normal Human Epidermal Keratinocytes and Human Squamous Cell Carcinoma,” Journal of Investigate Dermatology, 94(5), 657-661 (May 1990).
Dagle et al., “Targeted Degradation of mRNA inXenopus oocytesand Embryos Directed by Modified Oligonucleotides: Studies of An2 and Cyclin in Embryogenesis,” Nucleic Acids Research, 18(16), 4751-4757 (Aug. 25, 1990).
Hakimelahi et al., “Design, Synthesis, and Structure-Activity Relationship of Novel Dinucleotide Analogs as Agents Against Herpes and Human Immunodeficiency Viruses,” Journal of Medicinal Chemistry, 38(23), 4648-4659 (Nov. 10, 1995).
Naesens et al., “Anti-HIV Activity and Metaboli . . . ,” Poster Session 1, The Tenth International Conference on Antiviral Research, Hotel Nikko, Atlanta, GA, Apr. 6-11, 1997; published in Antiviral Research, 34(2), p. A54 (Abstract 40), Apr. 1997).
Evrard et al., “An in vitro Nucleoside Analog Screening Method for Cancer Gene Therapy,” Cell Biology and Toxicology, 12, 345-350 (1996).
Berkow et al. (eds.), The Merck Manual of Diagnosis and Therapy, 16th Ed., Merck & Co., Rahway, NJ, May 1992, only p. 1278 supplied.
Morrison & Boyd (eds.), Organic Chemistry, Allyn & Bacon, Inc., Boston, MA, 1973, only pp. 1170-1180 supplied.
L. B. Townsend (ed.), Chemistry of Nucleosides and Nucleotides, vol. 3, Plenum Press, New York, NY, 1974, only Table of Contents, Bibliography pp. 529-535, and Index pp. 537-552 supplied.
The American Heritage College Dictionary, Third Edition, Houghton Miffin Co., New York, NY, 1997, only p. 668 supplied.
Smith et al., “Second Passage Human Breast Cancer Cells,” Cancer Research, 50(10), 2943-2948 (May, 1990).
O'Neil et al. (eds.), The Merck Index, 13th Edition, Merck & Co., Whitehouse Station, NJ, 2001, only p. 1452 supplied, see Entry No. 8191 which identifies “Tomudex.”
Naesens et al., “Anti-HIV Activity and Metabolism of Phosphoramidate Derivatives of D4T-MP with Variations in the Amino Acid Moiety,” Poster Session 1, The Tenth International Conference on Antiviral Research, Hotel Nikko, Atlanta, GA, Apr. 6-11, 1997; Published inAntiviral Research, 34(2), p. A54 (Abstract 40), (Apr. 1997).
Berkow et al. (eds.)The Merck Manual of Diagnosis and Therapy, 16th Ed., Merck & Co., Rahway, NJ, May 1992, only p. 1278 supplied.
Morrison & Boyd (eds.),Organic Chemistry, Allyn & Bacon, Inc., Boston, MA, 1973, only pp. 1170-1180 supplied.
L. B. Townsend (ed.),Chemistry of Nucleosides and Nucleotides, vol. 3, Plenum Press, New York, NY, 1974, only Table of Contents, Bibliography pp
Celmed Oncology (USA), Inc.
Crane Lawrence E.
Jiang Shaojia Anna
LandOfFree
Methods for treating therapy-resistant tumors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating therapy-resistant tumors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating therapy-resistant tumors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3969971